![IDSA on Twitter: "A new CID study finds that seroconversion after SARS-CoV-2 infection confers protection against reinfection lasting at least 8 months, which may help global health authorities establish priorities for vaccine IDSA on Twitter: "A new CID study finds that seroconversion after SARS-CoV-2 infection confers protection against reinfection lasting at least 8 months, which may help global health authorities establish priorities for vaccine](https://pbs.twimg.com/media/E5FFrj7WUAEQBRR.png)
IDSA on Twitter: "A new CID study finds that seroconversion after SARS-CoV-2 infection confers protection against reinfection lasting at least 8 months, which may help global health authorities establish priorities for vaccine
![IDSA on Twitter: "A new article in CID describes trends and clinical characteristics among patients with SARS-CoV-2 vaccine-breakthrough infections who were hospitalized at a single center in Florida: https://t.co/45436fRglk #ClinInfectDis ... IDSA on Twitter: "A new article in CID describes trends and clinical characteristics among patients with SARS-CoV-2 vaccine-breakthrough infections who were hospitalized at a single center in Florida: https://t.co/45436fRglk #ClinInfectDis ...](https://pbs.twimg.com/media/FEFvpnRXMAghN-2.jpg)
IDSA on Twitter: "A new article in CID describes trends and clinical characteristics among patients with SARS-CoV-2 vaccine-breakthrough infections who were hospitalized at a single center in Florida: https://t.co/45436fRglk #ClinInfectDis ...
![USPHS/IDSA Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus | Clinical Infectious Diseases | Oxford Academic USPHS/IDSA Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus | Clinical Infectious Diseases | Oxford Academic](https://oup-silverchair-cdn-com.eres.qnl.qa/oup/backfile/Content_public/Journal/cid/Issue/21/Supplement_1/3/m_cover.jpeg?Expires=1637248455&Signature=Tz6Th5sBvyGM~XVALrcAj6Is7soS2PordiP9yAttQvbL38D0TnZ8EJoOOqtVpDsORB~TaK3xzXPVSLgwgomeodbHmM9sTqpAfEyfft4m7kwHeAel~hC-CoZbJ8gXydF0ESpTPjY6xcxmO-vO43ak~cljyDG7pAU~vGSOyRfITEf1P0emwfkrvj5LPtaS6Hfag~uK3A~DlmBgHTvVxEHJOKyxvXgYpU5PYcKfJPQMvDUjC6E-HdRx54WElGcWRPxYxo8ccU8FRlUDytvnvghKlDkOnWiKzBqk9zJOk2KyWtRVgKXE~XvosDr9BmRuNciTn~WECxaAsoiWaHZVb7J0Ag__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
USPHS/IDSA Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus | Clinical Infectious Diseases | Oxford Academic
![IDSA on Twitter: "IDSA is pleased to announce that @PaulSaxMD has been named the next editor-in-chief of Clinical Infectious Diseases. 🎉 #IDSAJournals #ClinInfectDis https://t.co/V6kHA6JvDd" / Twitter IDSA on Twitter: "IDSA is pleased to announce that @PaulSaxMD has been named the next editor-in-chief of Clinical Infectious Diseases. 🎉 #IDSAJournals #ClinInfectDis https://t.co/V6kHA6JvDd" / Twitter](https://pbs.twimg.com/media/FLPj2DgVQAgUvm0.jpg)
IDSA on Twitter: "IDSA is pleased to announce that @PaulSaxMD has been named the next editor-in-chief of Clinical Infectious Diseases. 🎉 #IDSAJournals #ClinInfectDis https://t.co/V6kHA6JvDd" / Twitter
Abraar Karan on Twitter: "New in CID Journal from the @BrighamWomens infection control team Increasing testing & N95 respirator use to control hospital-based clusters of #covid19 H/t @ABsteward https://t.co/gNie5kJqoz https://t.co/k7wh874NF5" / Twitter
![IDSA on Twitter: "A new multicenter case-control analysis in CID found that during March–May 2021, SARS-CoV-2 mRNA vaccines were highly effective at preventing COVID hospitalizations among U.S. adults. 📄:https://t.co/Hyj3whzd3d #IDSAJournals ... IDSA on Twitter: "A new multicenter case-control analysis in CID found that during March–May 2021, SARS-CoV-2 mRNA vaccines were highly effective at preventing COVID hospitalizations among U.S. adults. 📄:https://t.co/Hyj3whzd3d #IDSAJournals ...](https://pbs.twimg.com/media/E9w8gf5XMAA35zn.png)
IDSA on Twitter: "A new multicenter case-control analysis in CID found that during March–May 2021, SARS-CoV-2 mRNA vaccines were highly effective at preventing COVID hospitalizations among U.S. adults. 📄:https://t.co/Hyj3whzd3d #IDSAJournals ...
![IDSA on Twitter: "CID: During the 1st COVID-19 wave in South Africa, similar antibody responses were seen in people not infected w/ HIV & people w/ HIV on antiretroviral therapy, suggesting vaccines IDSA on Twitter: "CID: During the 1st COVID-19 wave in South Africa, similar antibody responses were seen in people not infected w/ HIV & people w/ HIV on antiretroviral therapy, suggesting vaccines](https://pbs.twimg.com/media/FAuEd5yX0AUGcQb.jpg)
IDSA on Twitter: "CID: During the 1st COVID-19 wave in South Africa, similar antibody responses were seen in people not infected w/ HIV & people w/ HIV on antiretroviral therapy, suggesting vaccines
![IDSA on Twitter: "A prospective cohort study in CID found that long-term COVID-19 symptoms were common, even in those with mild disease. Female and obese patients recovered more slowly, regardless of age IDSA on Twitter: "A prospective cohort study in CID found that long-term COVID-19 symptoms were common, even in those with mild disease. Female and obese patients recovered more slowly, regardless of age](https://pbs.twimg.com/media/FAtbfs9XEAEvvPF.jpg)